| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9aaf1e3d2c6dcc92638559c30b7f2ca6 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2770-20022
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12R1-19
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-522
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-575
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-523
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-542
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N1-205
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2770-20034
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12R2001-19 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-0258
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-215
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-70
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-74
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N1-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-005 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12R1-19 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-70
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-215
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-108
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N1-20 |
| filingDate |
2020-05-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2021-04-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_43c2c8263ef5645ec11615fd14925b14 |
| publicationDate |
2021-04-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-10973908-B1 |
| titleOfInvention |
Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine |
| abstract |
A live genetically engineered bacterium, comprising a genetically engineered construct comprising a nucleic acid sequence encoding at least one portion of a SARS-CoV-2 antigen, the live genetically engineered bacterium being adapted for administration to a human or animal and colonization of at least one tissue under non-lethal conditions. The antigen is preferably the SARS-CoV-2 spike protein. The nucleic acid sequence preferably includes an associated promoter. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2023002433-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2023044494-A3
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2022047697-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-113881742-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-113881692-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-114231497-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2021198376-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2023086796-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2022036159-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2022034221-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2023090772-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2021183456-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2023067450-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-112500494-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-112500494-B
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2022192093-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11406702-B1 |
| priorityDate |
2020-05-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |